(S (NP (NML (NN Phase) (NN I)) (ADJP (NN dose) (HYPH -) (VBG finding)) (NNS trials)) (VP (VBP are) (ADJP (RB increasingly) (JJ challenging) (SBAR (IN as) (S (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NN efficacy) (CC and) (NN toxicity))) (PP (IN of) (NP (NP (JJ new) (NNS compounds)) (-LRB- -LRB-) (CC or) (NP (NP (NN combination)) (PP (IN of) (NP (PRP them)))) (-RRB- -RRB-)))) (VP (VBZ becomes) (ADJP (RBR more) (JJ complex))))))) (. .))
(S (PP (IN Despite) (NP (DT this))) (, ,) (NP (NP (ADJP (RBS most) (RB commonly) (VBN used)) (NNS methods)) (PP (IN in) (NP (NP (NN practice) (NN focus)) (PP (IN on) (S (VP (VBG identifying) (NP (DT a) (NML (NNP Maximum)) (VBN Tolerated) (NN Dose) (PRN (-LRB- -LRB-) (NP (NN MTD)) (-RRB- -RRB-))) (PP (IN by) (S (VP (VBG learning) (ADVP (RB only)) (PP (IN from) (NP (NN toxicity) (NNS events)))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP present) (NP (NP (DT a) (JJ novel) (JJ adaptive) (JJ clinical) (NN trial) (NN methodology)) (, ,) (VP (VBN called) (NP (NP (NML (NNP Safe) (NNP Efficacy)) (NNP Exploration) (NNP Dose) (NNP Allocation) (PRN (-LRB- -LRB-) (NP (NNP SEEDA)) (-RRB- -RRB-))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBZ aims) (PP (IN at) (S (VP (VBG maximizing) (NP (DT the) (JJ cumulative) (NNS efficacies)) (PP (IN while) (S (VP (VBG satisfying) (NP (DT the) (NN toxicity) (NN safety) (NN constraint)) (PP (IN with) (NP (JJ high) (NN probability)))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP evaluate) (NP (NP (NN performance) (NNS objectives)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (NP (JJ operational) (NNS meanings)) (PP (IN in) (NP (JJ practical) (JJ clinical) (NNS trials))) (, ,) (PP (VBG including) (NP (NP (JJ cumulative) (NN efficacy)) (, ,) (NP (NML (NN recommendation) (HYPH /) (NN allocation)) (NN success) (NNS probabilities)) (, ,) (NP (NN toxicity) (NN violation) (NN probability)) (, ,) (CC and) (NP (NN sample) (NN efficiency)))))))))) (. .))
(S (NP (NP (NP (DT An) (JJ extended) (NML (NNP SEEDA) (HYPH -) (NNP Plateau)) (NN algorithm)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (VP (VBN tailored) (PP (IN for) (NP (DT the) (NN increase)))))))) (: -) (NP (NP (NML (RB then) (HYPH -) (NN plateau)) (NN efficacy) (NN behavior)) (PP (IN of) (NP (ADJP (RB molecularly) (VBN targeted)) (NNS agents)))) (PRN (-LRB- -LRB-) (NP (NN MTA)) (-RRB- -RRB-))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN presented))) (. .))
(S (PP (IN Through) (NP (NP (JJ numerical) (NNS experiments)) (VP (VBG using) (NP (NML (CC both) (NML (JJ synthetic)) (CC and) (NML (JJ real) (HYPH -) (NN world))) (NNS datasets))))) (, ,) (NP (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP (NNP SEEDA)) (VP (VBZ outperforms) (NP (ADJP (NN state) (HYPH -) (IN of) (HYPH -) (DT the) (HYPH -) (NN art)) (JJ clinical) (NN trial) (NNS designs)) (PP (IN by) (S (VP (VBG finding) (NP (DT the) (JJ optimal) (NN dose)) (PP (IN with) (NP (NP (JJR higher) (NN success) (NN rate)) (CC and) (NP (JJR fewer) (NNS patients))))))))))) (. .))
